BioCentury | Feb 28, 2005
Strategy

Curacyte's pipeline

Curacyte's pipeline Product Indication Status Origin Pyridoxalated hemoglobin polyoxyethylene (PHP) nitric oxide (NO) scavenger Distributive shock Ph III Curacyte Adjunct to high dose IL-2 treatment in RCC and melanoma Ph I Curacyte Cardiogenic shock Preclin...
BioCentury | Jun 17, 2002
Emerging Company Profile

Curacyte: Picking the best research

When Curacyte AG was founded in 2000, the company did not have a clear-cut technology or therapeutic focus. It had platforms in cancer and immunology and said it was developing therapies in cancer, immunodysregulation and...
Items per page:
1 - 2 of 2